Furthermore, RCT001, an optimized CXCR2 inhibitor, enhances the efficacy of anti-CTLA4 + anti-PD1 therapies by inhibiting tumor-associated M2 macrophages and tumor-associated neutrophils. This evidence concerns the gene CTLA4 and neoplasm.